LYRA Profile
Lyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of advanced drug delivery systems for the localized treatment of ear, nose, and throat (ENT) diseases. The company’s innovative XTreo technology platform is engineered to deliver therapeutic agents directly to targeted tissues, offering sustained release with a single administration. This approach aims to enhance treatment efficacy and patient compliance by addressing the limitations of traditional drug delivery methods in ENT care.
Lyra's pipeline includes several promising product candidates. LYR-210, a leading candidate, is an anti-inflammatory implantable drug matrix designed for the treatment of chronic rhinosinusitis (CRS). Currently in Phase II clinical trials, LYR-210 targets the underlying inflammation associated with CRS, aiming to provide long-term relief from symptoms. Additionally, LYR-220 is another key product under development, targeting CRS with and without nasal polyps. This candidate seeks to offer a new solution for patients with varying types of CRS, potentially addressing a broad patient population.
The company's focus on localized drug delivery reflects its commitment to improving treatment outcomes for ENT conditions. By leveraging the XTreo platform, Lyra Therapeutics aims to provide innovative solutions that address unmet medical needs in the management of chronic and acute ENT diseases. The technology's ability to deliver sustained drug release with minimal invasiveness represents a significant advancement in the field of ENT therapeutics.
Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was previously known as 480 Biomedical, Inc., adopting its current name in July 2018. The company’s ongoing research and development efforts underscore its dedication to advancing therapeutic solutions in the ENT domain, with a vision to improve patient care and treatment outcomes through its proprietary drug delivery technologies.
|
